HC Wainwright Issues Negative Forecast for AVBP Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Equities research analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for ArriVent BioPharma in a research report issued to clients and investors on Tuesday, May 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.95) for the quarter, down from their previous forecast of ($0.86). HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.99) EPS and FY2026 earnings at ($3.86) EPS.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Monday, April 20th. Oppenheimer restated an “outperform” rating and issued a $50.00 target price (up from $44.00) on shares of ArriVent BioPharma in a research note on Friday, March 6th. BTIG Research initiated coverage on ArriVent BioPharma in a research note on Thursday, March 12th. They issued a “buy” rating and a $42.00 target price for the company. B. Riley Financial lifted their target price on ArriVent BioPharma from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Finally, Citigroup decreased their target price on ArriVent BioPharma from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.78.

ArriVent BioPharma Stock Down 0.1%

Shares of AVBP stock opened at $28.93 on Thursday. The business has a 50 day moving average of $26.37 and a two-hundred day moving average of $23.29. ArriVent BioPharma has a 52 week low of $16.10 and a 52 week high of $32.14. The company has a market cap of $1.35 billion, a P/E ratio of -8.34 and a beta of 1.51.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.08).

Institutional Investors Weigh In On ArriVent BioPharma

Hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC raised its holdings in shares of ArriVent BioPharma by 8.5% during the third quarter. Suvretta Capital Management LLC now owns 3,703,452 shares of the company’s stock valued at $68,329,000 after buying an additional 290,664 shares during the last quarter. Anson Funds Management LP bought a new stake in shares of ArriVent BioPharma during the third quarter valued at approximately $1,843,000. Tema Etfs LLC bought a new stake in shares of ArriVent BioPharma during the fourth quarter valued at approximately $644,000. AlphaQuest LLC bought a new stake in shares of ArriVent BioPharma during the third quarter valued at approximately $765,000. Finally, Corient IA LLC bought a new stake in shares of ArriVent BioPharma during the third quarter valued at approximately $618,000. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.